Next Article in Journal
Extracellular Vesicles: Emerging Modulators of Cancer Drug Resistance
Next Article in Special Issue
Genetic Alterations in Childhood Acute Lymphoblastic Leukemia: Interactions with Clinical Features and Treatment Response
Previous Article in Journal
Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma
Previous Article in Special Issue
A Novel Platform to Test In Vivo Single Gene Dependencies in t(8,21) and t(15,17) AML Confirms Zeb2 as Leukemia Target
 
 
Review
Peer-Review Record

Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure

Cancers 2021, 13(4), 748; https://doi.org/10.3390/cancers13040748
by Hélène Pasquer 1,2, Maëlys Tostain 1,2, Nina Kaci 1,2, Blandine Roux 1,2 and Lina Benajiba 1,2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2021, 13(4), 748; https://doi.org/10.3390/cancers13040748
Submission received: 29 December 2020 / Revised: 24 January 2021 / Accepted: 1 February 2021 / Published: 11 February 2021
(This article belongs to the Special Issue Genomic Alterations of Leukemia)

Round 1

Reviewer 1 Report

The review written by Hélène Pasquer et al is suitable for publication being a comprehensive paper. However, I had some recommendations that may increase the interest of the readers.

The authors may describe in details the therapies for AML and the differences between elderly and young AML patients. Also, even if is not the aim of the paper, the importance of marker expression compared to genetics may be shortly noticed.

The papers published by Cancers Journal - Recently Approved Therapies and Drugs in Development by Michele Stanchina , Acute Myeloid Leukemia: Aging and Epigenetics by Polina Zjablovskaja et al and Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity by Marlon Arnone may be useful (for example).

One Graphical abstract may increased the interest of the readers.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

The manuscript is well written, it is readable. The authors describe a step-by-step genetic investigation from history to state-of-the-art methods that have enabled a better understanding of AML leukemogenesis. This led to direct clinical implications, namely determination of prognosis, MRD monitoring and the introduction of new targeted therapies. The paper contains brief / clear summaries in the form of schematic diagrams or tables.

I only recommend changing the information on the prognostic importance of the expression status of PB mRNA WT1 and supplementing the data according to the latest studies, e.g. Salek C. Clin Lymphoma Myeloma Leuk. 2020; Goel H. Am J Blood Res. 2020;  Rautenberg C. Blood Cancer J. 2019.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop